Teko ea COVID e Khutlile ka Tlhokahalo e Phahameng Ka lebaka la Omicron

New York City, eo hona joale e seng e le sehloho sa seoa sena ho la US, e tlalehile linyeoe tse ka bang 50,000 24 ka la XNUMX Tšitoe feela. Ena ke kakaretso e phahameng ka ho fetisisa ea letsatsi le le leng seterekeng ho tloha ha seoa sena se qala.

Joalo ka 2020, spike ea naha ka bophara maemong a bile kotsi moruong ka lebaka la lithibelo, tse ammeng liketsahalo tsa lipapali, likepe, haholo maeto, ka lifofane tse likete li hlakotsoe mafelo-bekeng a phomolo. Lefats'eng ka bophara, lifofane li hlakotse lifofane tse fetang 6,000 ka Mantsiboea a Keresemese, Keresemese le letsatsi kamora Keresemese, ho latela FlightAware. Todos Medical Ltd., Pfizer Inc., Moderna, Inc., Inovio Pharmaceuticals, Inc., Merck & Co., Inc.

Ho ea ka Anthony S. Fauci, moeletsi ea ka sehloohong oa bongaka ho Mopresidente Biden, ho tla ba bohlokoa haholo, "hore re fumane bokhoni bo boholo ba tlhahlobo, haholoholo ha tlhoko ea tlhahlobo e le holimo haholo, hammoho le motsoako oa mofuta oa Omicron ka boeona. , hammoho le nako ea matsatsi a phomolo, moo batho ba batlang ho fumana kholiseho e eketsehileng ea hore ba sirelelitsoe, esita le haeba u entoa le ho matlafatsoa.”

Todos Medical Ltd e phatlalalitse maobane hore, "CIA / CAP PCR ea eona e ikemetseng le laboratori ea tlhahlobo ea cPass e thibelang likokoana-hloko tsa COVID-19 Provista Diagnostics e fihletse rekoto e latellanang ea beke le beke ea tlhahlobo ea COVID PCR bakeng sa libeke tsa la 13 Tšitoe 2021 le la 20 Tšitoe 2021. Lipalo tsa liteko tsa COVID PCR li ne li khannoa haholo ke khoebo ea lab ea litšupiso ho tsoa lab ea tlhahlobo ea PCR e New York e neng e sa khone ho phethahatsa tlhoko ea tlhahlobo sebakeng sa eona. Khamphani e boetse e kene tumellanong e ncha ea lits'ebeletso tsa laboratori le ngaka e thehiloeng New Jersey bakeng sa Tlhahlobo ea PCR ea COVID le tlhahlobo ea COVID cPass e thibelang li-antibody.

"Tlhoko ea tlhahlobo ea PCR e ntse e eketseha ka potlako lipokothong tsa United States, 'me re lebelletse hore sena se tla tsoela pele ho feta matsatsi a phomolo ha batho ka bomong, likolo le bahiri ba batla ho theha libaka tse sireletsehileng, haholo-holo libakeng tse nang le litekanyetso tse tlaase tsa ente," ho boletse Gerald E. Commissiong, Mopresidente le CEO oa Todos Medical, k'hamphani ea motsoali ea Provista Diagnostics. 'Ka lebaka la taelo e ntseng e emetse ea' ente kapa tlhahlobo 'ho tsoa ho Tsamaiso ea Biden e tla beha litlhoko tsa tlhahlobo ho 38% ea batho ba baholo ba US ba e-so enteloe ka botlalo khahlanong le COVID-19, re bona khaello ea morao-rao ea tlhahlobo e kopantsoeng le e emetse taelo ea ho theha tlhokahalo ea keketseho e kholo ea tlhahlobo ea nako e telele ea COVID PCR ea Provista. Ha o eketsa bokhoni ba Omicron ba ho qoba ente kapa boits'ireletso bo fumanoeng ke ts'oaetso, le liqholotso tsa phihlello le ts'epahalo ea liteko tse potlakileng tsa antigen tse tsebahalang haholo tse fanang ka liphetho tse fosahetseng tsa leshano, tlhahlobo ea COVID PCR ka nako ea phetoho e potlakileng e hlaha e le mohloli o tšepahalang le o tšepahalang. ea tlhahisoleseling ho tseba boemo ba motho ba ts'oaetso ea COVID.'

Mong. Commissiong o ile a tsoela pele, 'Ho feta moo, ha o kopanya lintlha tsena le ts'ebetso ea morao-rao ea thahasello ho li-booster to buttress ente kapa ts'oaetso e fumanoeng ke ts'oaetso khahlanong le Omicron, re qala ho bona keketseho e kholo ea thahasello bakeng sa tlhahlobo ea cPass neutralizing antibody ho beha leihlo. maemo a potolohang a fokotsang li-antibody liteko le ho lumella bakuli ho etsa liqeto tse potlakileng, tse tsamaisoang ke data ho fumana lithunya tsa bona tse matlafatsang, haholo ha ho fanoa ka lintlha tse hlahang tse fanang ka maikutlo a hore li-anti-titer tse phahameng tse hlahisoang ke sethunya sa morao-rao ke tsona tse ka sireletsang motho khahlano le Omicron. tšoaetso.'

Lintlha tsa morao-rao tse hlahang Iseraele li fana ka maikutlo a ho fokotsa li-anti-titers ka lebaka la ente ea Pfizer/BioNTech Comirnaty e qala ho fokotseha ka mor'a likhoeli tse 4 ho tloha ho ente e feletseng, 'me lithunya tse matlafatsang tsa Comirnaty li qala ho fokotseha ka mor'a libeke tse 10 ho tloha ho thunngoa ea booster. Thunya ea bone ("Booster ea Bobeli") e sa tsoa fuoa tumello naheng ea Israel bakeng sa batho ba nang le ts'oaetso ea 'mele ea ho itšireletsa mafung le ba 60+, 'me ho ntse ho etsoa boithuto ho fumana hore na ho na le nako e telele hakae ea Booster ea Bobeli bakeng sa batho ka kakaretso.

Pfizer Inc. e phatlalalitse bekeng e fetileng hore Tsamaiso ea Lijo le Lithethefatsi ea US (FDA) e lumelletse ts'ebeliso ea tšohanyetso ea matlapa a PAXLOVID ™ (nirmatrelvir [PF-07321332] le matlapa a ritonavir) bakeng sa kalafo ea COVID-19 e bobebe ho isa ho e itekanetseng ho batho ba baholo. le bakuli ba bana (ba lilemo li 12 ho ea holimo ba boima ba bonyane lik'hilograma tse 40 [88 lbs]) ba nang le liphetho tse ntle tsa tlhahlobo e tobileng ea vaerase ea SARS-CoV-2, 'me ba kotsing e kholo ea ho fetela ho COVID-19 e matla, ho kenyeletsoa ho kena sepetlele kapa lefu. Kalafo e kenyelletsa nirmatrelvir, inhibitor ea mantlha ea protease (Mpro) e tsoang lilaboratoring tsa Pfizer, e neng e etselitsoe ho thibela ts'ebetso ea SARS-CoV-2 Mpro, enzyme eo coronavirus e hlokang ho e etsa. "Tumello ea kajeno ea PAXLOVID e emela mohlala o mong o motle oa kamoo mahlale a tla re thusa ho hlola seoa sena, seo le lilemo tse peli ho feta, se ntseng se tsoela pele ho senya le ho senya maphelo a batho lefatšeng ka bophara. Kalafo ena ea katleho, e bonts'itsoeng e fokotsa haholo lipetlele le lefu mme e ka isoa hae, e tla fetola tsela eo re tšoarang COVID-19 ka eona, 'me ka tšepo e tla thusa ho fokotsa likhatello tse kholo tse tobaneng le lits'ebeletso tsa rona tsa bophelo bo botle le lipetlele," ho boletse Albert. Bourla, Molula-setulo le Ofisiri e ka Sehloohong ea Phethahatso, Pfizer. "Pfizer e ikemiselitse ho qala ho beleha US hang-hang ho thusa ho kenya PAXLOVID matsohong a bakuli ba loketseng kapele kamoo ho ka khonehang."

Moderna, Inc. e phatlalalitse ka la 20 Tšitoe, data ea pele ea anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-anti-body-anti-anti-anti-anti-anti-anti-anti-anti-o-o-o-ommeng e latelang bakhethoa ba Khamphani ba matlafatsoa ke litekanyetso tsa 50 µg le 100 µg. 50 μg booster ea mRNA-1273 e lumelletsoeng hajoale e ekelitse maemo a antibody khahlano le Omicron hoo e ka bang makhetlo a 37 ha ho bapisoa le maemo a pele ho boost mme tekanyetso ea 100 µg ea mRNA-1273 e ekelitse maemo a anti-antibody hoo e ka bang makhetlo a 83 ha a bapisoa le maemo a pele ho boost. "Keketseho e makatsang ea linyeoe tsa COVID-19 ho tsoa ho mofuta oa Omicron e ama bohle. Leha ho le joalo, lintlha tsena tse bonts'ang hore booster e lumelletsoeng hajoale ea Moderna COVID-19 e ka eketsa maemo a antibody ka makhetlo a 37 ho feta maemo a pele ho matla aa khothatsa, "ho boletse Stéphane Bancel, Ofisiri e Moholo oa Moderna. "Ho arabela phapanong ena e tšoaetsanoang haholo, Moderna e tla tsoelapele ho ntšetsa pele motho ea ikhethileng ka ho khetheha oa Omicron litekong tsa bongaka haeba ho ka hlokahala nakong e tlang. Hape re tla tsoelapele ho hlahisa le ho arolelana datha ho pholletsa le maano a rona a matlafatso le balaoli ba bophelo bo botle ba sechaba ho ba thusa ho etsa liqeto tse thehiloeng bopaking mabapi le maano a matle a ente khahlano le SARS-CoV-2. ”

Inovio Pharmaceuticals, Inc. e phatlalalitse lintlafatso tsa khoeli e fetileng lenaneong la Phase 3 bakeng sa VGX-3100 bakeng sa HPV-e amahanngoang le cervical high-grade squamous intraepithelial lesions (HSIL), ho kenyeletsoa tatellano ea selemo e le 'ngoe ea lintlha tsa ts'ebetso le polokeho ho barupeluoa ba REVEAL1. , ho phethela ho ingolisa ho REVEAL2, le ho ntšetsa pele mokhethoa oa eona oa biomarker pele ho kalafo bakeng sa VGX-3100 hore e ntlafatsoe le QIAGEN. Ho feta moo, molekane oa nts'etsopele ea INOVIO ka har'a Chaena e Kholo (China bohareng, Hong Kong, Macao, Taiwan), ApolloBio Corp. (“ApolloBio”), o file monkakarolo oa pele tekong e arohaneng ea Mokhahlelo oa 3 Chaena. Dr. J. Joseph Kim, Mopresidente le CEO oa INOVIO, o itse, "Re ntse re hatela pele ka matla ho nts'etsopele ea INOVIO's immunotherapies e alafang HPV-associated cervical HSIL. Ha e sa phekoloe, HSIL ea molomo oa popelo e ka fetela ho mofetše. VGX-3100 e na le monyetla oa ho ba mofuta oa pele o amohetsoeng oa immunotherapy le mokhoa o sa buuoeng bakeng sa basali ba nang le HSIL ea molomo oa popelo 'me re lebelletse ho ntšetsa pele boiteko ba rona ho tsoa lithutong tsa rona tsa Mokhahlelo oa 3 ka khoebo.

Merck & Co., Inc. e phatlalalitse pejana khoeling ena hore New England Journal of Medicine e phatlalalitse liphetho ho tsoa tekong ea Phase 3 ea MOVe-OUT e hlahlobang molnupiravir, moriana o thibelang likokoana-hloko oa lipatlisiso, ho batho ba baholo bao e seng ba sepetlele ba kotsing e kholo ba nang le COVID e bobebe ho isa ho e itekanetseng. -19. Lintlha tse tsoang ho MOVe-OUT li bonts'itse hore kalafo ea pele ka molnupiravir e fokolitse haholo kotsi ea ho kena sepetlele kapa lefu le kotsing e kholo, batho ba baholo ba sa entoeng ba nang le COVID-19. Merck e nts'etsapele molnupiravir ka ts'ebelisano le Ridgeback Biotherapeutics. Molnupiravir e lumelletsoe United Kingdom joalo ka antiviral ea pele ea molomo bakeng sa kalafo ea COVID-19 e bobebe ho isa ho e itekanetseng ho batho ba baholo ba nang le tlhahlobo e ntle ea tlhahlobo ea SARS-CoV-2 mme bonyane ba nang le kotsi e le 'ngoe ea ho tšoaroa ke bokuli bo matla. European Medicines Agency (EMA) e fane ka maikutlo a matle a saense bakeng sa molnupiravir tlasa Article 5.3 Regulation 726/2004, e reretsoeng ho ts'ehetsa liqeto tsa naha mabapi le ts'ebeliso e ka bang teng ea molnupiravir pele ho tumello ea ho bapatsa. Likopo tsa taolo li ntse li hlahlojoa kapa li mothating oa ho romelloa, ho kenyelletsa le likopo tsa Tumello ea Tšebeliso ea Tšohanyetso (EUA) ke Tsamaiso ea Lijo le Lithethefatsi ea US (FDA) le Lekala la Bophelo bo Botle, Basebetsi le Boiketlo ba Japane.